Evidence map›Paper›PMID 32607894›Full record

ArticleDrug safety2020

Correction to: Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study.

Sieta T de Vries, Maartje J M van der Sar, Anna Marie Coleman, Yvette Escudero, Alfonso Rodríguez Pascual, Miguel-Ángel Maciá Martínez, Amelia Cupelli, Ilaria Baldelli, Ivana Šipić, Adriana Andrić and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug safety, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Sieta T de VriesDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-6090-2434
Maartje J M van der SarDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Anna Marie ColemanHealth Products Regulatory Authority (HPRA), Dublin, Ireland.
Yvette EscuderoSpanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain.
Alfonso Rodríguez PascualSpanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain.
Miguel-Ángel Maciá MartínezSpanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain.
Amelia CupelliItalian Medicines Agency (AIFA), Rome, Italy.
Ilaria BaldelliItalian Medicines Agency (AIFA), Rome, Italy.
Ivana ŠipićAgency for Medicinal Products and Medical Devices of Croatia (HALMED), Zagreb, Croatia.
Adriana AndrićAgency for Medicinal Products and Medical Devices of Croatia (HALMED), Zagreb, Croatia.
Line MichanDanish Medicines Agency (DKMA), Copenhagen, Denmark.
Petra DenigDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Peter G M MolDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. p.g.m.mol@umcg.nl.
SCOPE work package 6

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the original publication of the article, the headings of columns 3 and 4 in the data table.

Identifiers

PMID32607894
PMCPMC7645582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.